Molecular bases of the poor response of liver cancer to chemotherapy
- Publication type:
- Journal article
- Metadata:
-
- Autoren
- Jose JG Marin
- Oscar Briz
- Elisa Herraez
- Elisa Lozano
- Maitane Asensio
- Silvia Di Giacomo
- Marta R Romero
- Luis M Osorio-Padilla
- Ana I Santos-Llamas
- Maria A Serrano
- Carolina Armengol
- Thomas Efferth
- Rocio IR Macias
- Autoren-URL
- https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=fis-test-1&SrcAuth=WosAPI&KeyUT=WOS:000433903400008&DestLinkType=FullRecord&DestApp=WOS_CPL
- DOI
- 10.1016/j.clinre.2017.12.006
- eISSN
- 2210-741X
- Externe Identifier
- Clarivate Analytics Document Solution ID: GH8FR
- PubMed Identifier: 29544679
- ISSN
- 2210-7401
- Ausgabe der Veröffentlichung
- 3
- Zeitschrift
- CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY
- Schlüsselwörter
- Cholangiocarcinoma
- Hepatoblastoma
- Hepatocellular carcinoma
- Multidrug resistance
- Targeted therapies
- Paginierung
- 182 - 192
- Datum der Veröffentlichung
- 2018
- Status
- Published
- Titel
- Molecular bases of the poor response of liver cancer to chemotherapy
- Sub types
- Review
- Ausgabe der Zeitschrift
- 42
Data source: Web of Science (Lite)
- Other metadata sources:
-
- Autoren
- Jose JG Marin
- Oscar Briz
- Elisa Herraez
- Elisa Lozano
- Maitane Asensio
- Silvia Di Giacomo
- Marta R Romero
- Luis M Osorio-Padilla
- Ana I Santos-Llamas
- Maria A Serrano
- Carolina Armengol
- Thomas Efferth
- Rocio IR Macias
- DOI
- 10.1016/j.clinre.2017.12.006
- ISSN
- 2210-7401
- Ausgabe der Veröffentlichung
- 3
- Zeitschrift
- Clinics and Research in Hepatology and Gastroenterology
- Sprache
- en
- Paginierung
- 182 - 192
- Datum der Veröffentlichung
- 2018
- Status
- Published
- Herausgeber
- Elsevier BV
- Herausgeber URL
- http://dx.doi.org/10.1016/j.clinre.2017.12.006
- Datum der Datenerfassung
- 2022
- Titel
- Molecular bases of the poor response of liver cancer to chemotherapy
- Ausgabe der Zeitschrift
- 42
Data source: Crossref
- Abstract
- A characteristic shared by most frequent types of primary liver cancer, i.e., hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) in adults, and in a lesser extent hepatoblastoma (HB) mainly in children, is their high refractoriness to chemotherapy. This is the result of synergic interactions among complex and diverse mechanisms of chemoresistance (MOC) in which more than 100 genes are involved. Pharmacological treatment, although it can be initially effective, frequently stimulates the expression of MOC genes, which results in the relapse of the tumor, usually with a more aggressive and less chemosensitive phenotype. Identification of the MOC genetic signature accounting for the "resistome" present at each moment of tumor life would prevent the administration of chemotherapeutic regimens without chance of success but still with noxious side effects for the patient. Moreover, a better description of cancer cells strength is required to develop novel strategies based on pharmacological, cellular or gene therapy to overcome liver cancer chemoresistance.
- Addresses
- Experimental Hepatology and Drug Targeting (HEVEFARM), University of Salamanca, IBSAL, Salamanca, Spain; Center for the Study of Liver and Gastrointestinal Diseases (CIBERehd), Carlos III National Institute of Health, Madrid, Spain. Electronic address: jjgmarin@usal.es.
- Autoren
- Jose JG Marin
- Oscar Briz
- Elisa Herraez
- Elisa Lozano
- Maitane Asensio
- Silvia Di Giacomo
- Marta R Romero
- Luis M Osorio-Padilla
- Ana I Santos-Llamas
- Maria A Serrano
- Carolina Armengol
- Thomas Efferth
- Thomas Efferth
- Rocio IR Macias
- DOI
- 10.1016/j.clinre.2017.12.006
- eISSN
- 2210-741X
- Externe Identifier
- PubMed Identifier: 29544679
- Open access
- false
- ISSN
- 2210-7401
- Ausgabe der Veröffentlichung
- 3
- Zeitschrift
- Clinics and research in hepatology and gastroenterology
- Schlüsselwörter
- Humans
- Carcinoma, Hepatocellular
- Cholangiocarcinoma
- Liver Neoplasms
- Drug Resistance, Neoplasm
- Sprache
- eng
- Medium
- Print-Electronic
- Online publication date
- 2018
- Paginierung
- 182 - 192
- Datum der Veröffentlichung
- 2018
- Status
- Published
- Datum der Datenerfassung
- 2018
- Titel
- Molecular bases of the poor response of liver cancer to chemotherapy.
- Sub types
- Review
- Journal Article
- Ausgabe der Zeitschrift
- 42
Data source: Europe PubMed Central
- Abstract
- A characteristic shared by most frequent types of primary liver cancer, i.e., hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) in adults, and in a lesser extent hepatoblastoma (HB) mainly in children, is their high refractoriness to chemotherapy. This is the result of synergic interactions among complex and diverse mechanisms of chemoresistance (MOC) in which more than 100 genes are involved. Pharmacological treatment, although it can be initially effective, frequently stimulates the expression of MOC genes, which results in the relapse of the tumor, usually with a more aggressive and less chemosensitive phenotype. Identification of the MOC genetic signature accounting for the "resistome" present at each moment of tumor life would prevent the administration of chemotherapeutic regimens without chance of success but still with noxious side effects for the patient. Moreover, a better description of cancer cells strength is required to develop novel strategies based on pharmacological, cellular or gene therapy to overcome liver cancer chemoresistance.
- Date of acceptance
- 2017
- Autoren
- Jose JG Marin
- Oscar Briz
- Elisa Herraez
- Elisa Lozano
- Maitane Asensio
- Silvia Di Giacomo
- Marta R Romero
- Luis M Osorio-Padilla
- Ana I Santos-Llamas
- Maria A Serrano
- Carolina Armengol
- Thomas Efferth
- Rocio IR Macias
- Autoren-URL
- https://www.ncbi.nlm.nih.gov/pubmed/29544679
- DOI
- 10.1016/j.clinre.2017.12.006
- eISSN
- 2210-741X
- Ausgabe der Veröffentlichung
- 3
- Zeitschrift
- Clin Res Hepatol Gastroenterol
- Schlüsselwörter
- Cholangiocarcinoma
- Hepatoblastoma
- Hepatocellular carcinoma
- Multidrug resistance
- Targeted therapies
- Carcinoma, Hepatocellular
- Cholangiocarcinoma
- Drug Resistance, Neoplasm
- Humans
- Liver Neoplasms
- Sprache
- eng
- Country
- France
- Paginierung
- 182 - 192
- PII
- S2210-7401(18)30029-9
- Datum der Veröffentlichung
- 2018
- Status
- Published
- Datum, an dem der Datensatz öffentlich gemacht wurde
- 2019
- Titel
- Molecular bases of the poor response of liver cancer to chemotherapy.
- Sub types
- Journal Article
- Review
- Ausgabe der Zeitschrift
- 42
Data source: PubMed
- Beziehungen:
- Property of